Select Page

AACR: HER2 targeted therapy shows promise in previously treated lung cancers
“Key Takeaways: Zongertinib, a HER2-targeted therapy made by Boehringer Ingelheim, demonstrated promising results in HER2-mutant lung cancer. These cancers are associated with resistance to standard therapies and a very poor prognosis. As an oral pill, zongertinib would be a more convenient option for patients. Trial data prompted a priority review by the Food and Drug Administration (FDA) earlier this year and sparked a Phase II trial comparing it to the current standard of care. Additional cancer types are under investigation.”

Potential New Treatment for KRAS-GI2D Lung Cancer Reported in First-of-Its-Kind Clinical Trial
“Now, for the first time, a drug taking aim at the mutation subtype called KRAS-G12D is showing promise in a phase 1 trial for patients with non-small cell lung cancer (NSCLC) . The drug is an experimental targeted therapy called zoldonrasib (RMC-9805). The KRAS-G12D mutation is rare (appearing in about 4% of all NSCLCs) but can be found in a wide range of patients, including in younger patients who have never smoked.”

Pregnancy-Related Proteins in Tumors Linked to Worse Survival in Female Lung Cancer Patients
“Lung cancer can co-opt genes that normally help a fetus develop and evade the mother’s immune system. And while these pregnancy-specific glycoproteins (PSGs) can get activated in the cancers of both men and women, female patients had poorer outcomes, a Memorial Sloan Kettering Cancer Center (MSK) research team has found.”

Researchers develop urine test for early detection of lung cancer
“A groundbreaking new urine test could soon help spot the early warning signs of lung cancer long before symptoms appear. Scientists at the University of Cambridge, led by Professor Ljiljana Fruk and Dr. Daniel Muñoz-Espín, have developed the first test of its kind.”

Onc.AI’s model improves lung cancer survival predictions in GSK-run study
“Onc.AI announced on Friday findings from a research collaboration with GSK that showed its AI-powered Serial CT Response Score (CTRS) improved overall survival (OS) predictions compared to traditional surrogates in patients with non–small-cell lung cancer (NSCLC) taking GSK’s anti–PD-1 checkpoint inhibitor Jemperli (dostarlimab) in the GARNET Phase I trial. Results from the study will be presented at the American Association for Cancer Research (AACR) meeting on Sunday.”

Roswell Park Expert to Share Promising Results on New Immunotherapy Approach in Non-Small Cell Lung Cancer
“Newswise — BUFFALO, N.Y. and CHICAGO — Patients with advanced non-small cell lung cancer (NSCLC) are often treated with immunotherapy drugs known as checkpoint inhibitors, which are designed to strengthen the immune system’s ability to kill cancer cells — but these drugs do not produce a lasting response in most patients with this cancer type. Initial results of a phase 1 clinical trial of the investigational drug JNJ-86974680 reveal that it has the potential to overcome that limitation.”

Participation in Lung Health Cohort Research Study Leads to Early Cancer Diagnosis
“Cindy was a healthy, 35-year-old woman with no symptoms of cancer when she joined the American Lung Association’s Lung Health Cohort Study, a research study with the goal of following 4,000 young, healthy adults for approximately five years, to start identifying risk factors for lung diseases.”

Protein Implicated as Driver of Lung Cancer
“Northwestern Medicine scientists have uncovered how a testis-specific protein contributes to tumor growth and progression in lung cancer, according to a study published in Science Advances.”

‘Considerable’ rates of lung cancer found among individuals with no known risk factors
“A new study published in JAMA reveals “considerable” rates of lung cancer among individuals with no known risk factors. Low dose computed tomography (LDCT) has been proven as an effective screening tool for lung cancer based on randomized clinical trials among seniors and current and former smokers. However, previous studies have shown rising rates of the disease for younger individuals and nonsmokers, especially in Asia, experts noted.”

American College of Radiology announces significant expansion of Lung Cancer Screening Registry
“The American College of Radiology (ACR) has announced significant changes to its Lung Cancer Screening Registry. In fact, the registry is getting a whole new name—and will be known as the Early Lung Cancer Detection Registry by the end of 2025.”

University of California Lung Cancer Consortium and AstraZeneca Expand Healthy Lungs California Initiative to Improve Early Lung Cancer Detection and Screening Statewide
“This five-year partnership brings together researchers from across five University of California campuses—UC Davis, UC Irvine, UCLA, UC San Diego and UCSF—coordinated through the UC Lung Cancer Consortium and led by Amy L. Cummings, M.D., Ph.D., a thoracic oncologist and research scientist at the UCLA Jonsson Comprehensive Cancer Center. The collaboration will address current barriers to early lung cancer detection and screening.”

Breast cancer drug Supinoxin shows potential for small-cell lung cancer in new tests
“Tran and co-principal investigator Bennett Elzey, research associate professor of comparative pathobiology in the College of Veterinary Medicine, have published their results in the journal iScience. The team suggests that Supinoxin will more effectively treat tumors when combined with another therapeutic. The latest experiments probed the effects of Supinoxin on DDX5 protein activity in cancerous human cell lines and in an animal model.”

Ivonescimab in Combination with Chemotherapy Demonstrates Statistically Significant and Strongly Positive Results in First-Line Treatment of Squamous Non-Small Cell Lung Cancer (sq-NSCLC) vs. Tislelizumab in Combination with Chemotherapy
“HONG KONG, April 22, 2025 /PRNewswire/ — Akeso, Inc. (9926.HK) (“Akeso” or the “Company”) is both pleased and honored to announce that its global first-in-class PD-1/VEGF bispecific antibody, ivonescimab, in combination with chemotherapy, has demonstrated strongly positive results in the Phase III clinical trial (AK112-306/HARMONi-6) for first-line treatment of advanced squamous non-small cell lung cancer (sq-NSCLC). The Independent Data Monitoring Committee (IDMC) declared that the study had met its primary endpoint of progression-free survival (PFS) at the first pre-specified interim analysis. The results of HARMONi-6 study are both statistically significant and clinically meaningful.”